Rafael Holdings Inc. (NYSE: RFL) is having one of those days that micro-cap biotech investors know all too well. The stock is trading sharply lower on Wednesday after the company released topline efficacy and safety findings from its subsidiary Cyclo Therapeutics LLC's pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C (NPC).

With a market capitalization of just $105.6 million at the previous close, Rafael was always going to be vulnerable to violent swings on clinical trial news. And violent it was. About 1.90 million shares changed hands during the session, more than 12 times the 100-day average volume of roughly 155,467 shares, according to market data.

The Endpoint Miss, and the Silver Lining

Here's the tricky part: the trial missed its primary endpoint, but the drug still showed a directionally favorable treatment effect, slowing disease progression by 64% at Week 96. That didn't reach statistical significance overall, but a prespecified subgroup analysis did.

The 96-week trial evaluated 94 patients aged 3 to 70 who received either 2000 mg/kg of intravenous Trappsol Cyclo every two weeks or a placebo. In a prespecified subgroup representing 83% of participants on background miglustat or leucine therapy, the candidate slowed disease progression by 71% compared to placebo, achieving statistical significance. That's the kind of result that keeps a drug developer on target for a regulatory filing later this year.

Safety and Survival Signals

The treatment exhibited a well-tolerated safety profile consistent with underlying NPC symptoms. Treatment-emergent adverse events affected 93.8% of the Trappsol Cyclo cohort versus 100% in the placebo group. Serious treatment-related adverse events occurred at similar rates between the drug group (3.1%) and placebo (3.3%).

Hearing-related events affected 15.6% of treated patients and 13.3% of placebo patients, with one severe case of bilateral deafness reported in the treatment arm. One patient discontinued treatment early due to an adverse event, and no deaths occurred during the trial.

A separate overall survival study compared infantile-onset NPC patients against real-world controls. Trappsol Cyclo administration correlated with an 85% lower mortality risk compared to matched registry controls. Expanding the historical control cohort to include additional published studies revealed a 94% reduction in mortality risk.

Following a prior pre-NDA meeting with the FDA, the company expects to submit a New Drug Application in the fourth quarter of 2026.

RFL Price Action: Rafael Holdings shares were down 37.89% to $1.26 at the time of publication on Wednesday, according to market data.